Compare Recursion Pharmaceuticals Inc (RXRX) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Yum China Holdings Inc trades at $47.69 (market cap $16.28B). The key difference: Yum China Holdings Inc is far larger — about 9× Recursion Pharmaceuticals Inc's market cap, and Yum China Holdings Inc pays a 2.44% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | YUMC | |
|---|---|---|
Market Cap | $1.81B | $16.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $57.95 |
52-Week Low | $2.84 | $40.18 |
Enterprise Value | $1.33B | $17.19B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
YUMC trades at $47.77, down 0.87% today, with a bullish technical signal from moving averages and strong fundamental performance. The company reported Q2 2026 EPS of $0.70, beating estimates, and revenue growth of 13% year-over-year. Recent completion of the Pizza Hut brand acquisition in Mainland China for $1.2 billion enhances strategic control and potential margin expansion.
Outlook remains positive with consistent earnings beats and analyst consensus favoring a buy rating. Key risks include macroeconomic headwinds in China and integration challenges from the acquisition. The stock offers growth potential with a reasonable P/E of 17.43 and a projected 26.2% upside based on Wall Street targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
